Search research articles
Contact Us
Filters
Showing results (61-70 of 111) with videos related to
Page
of 12
Sort By:
Muscle & Nerve
|
January 4, 2020
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
Namita A Goyal, James D Berry, Anthony Windebank, et al.
Muscle & Nerve
|
December 12, 2022
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Angela Genge, Gary L Pattee, Gen Sobue, et al.
Plos Medicine
|
October 31, 2024
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial
Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, et al.
Muscle & Nerve
|
June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)
Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.
Muscle & Nerve
|
December 23, 2025
Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis
Angela Genge, Jeffrey Rothstein, Shari De Silva, et al.
Neurodegenerative Disease Management
|
November 24, 2021
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design
Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, et al.
Journal of Medical Economics
|
March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS
Paulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Journal of Neurology
|
January 28, 2024
Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology
Pedram Parnianpour, Michael Benatar, Hannah Briemberg, et al.
Human Brain Mapping
|
December 15, 2021
Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis
Abdullah Ishaque, Daniel Ta, Muhammad Khan, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
April 18, 2018
Understanding the use of NIV in ALS: results of an international ALS specialist survey
Terry D Heiman-Patterson, Merit E Cudkowicz, Mamede De Carvalho, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 111) with videos related to
Sort By:
Page
of 12
Muscle & Nerve
|
January 4, 2020
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
Namita A Goyal, James D Berry, Anthony Windebank, et al.
Muscle & Nerve
|
December 12, 2022
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
Angela Genge, Gary L Pattee, Gen Sobue, et al.
Plos Medicine
|
October 31, 2024
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial
Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, et al.
Muscle & Nerve
|
June 6, 2025
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)
Jeffrey Rothstein, Angela Genge, Shari De Silva, et al.
Muscle & Nerve
|
December 23, 2025
Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis
Angela Genge, Jeffrey Rothstein, Shari De Silva, et al.
Neurodegenerative Disease Management
|
November 24, 2021
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design
Björn Oskarsson, Nicholas Maragakis, Richard S Bedlack, et al.
Journal of Medical Economics
|
March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS
Paulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Journal of Neurology
|
January 28, 2024
Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology
Pedram Parnianpour, Michael Benatar, Hannah Briemberg, et al.
Human Brain Mapping
|
December 15, 2021
Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis
Abdullah Ishaque, Daniel Ta, Muhammad Khan, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
April 18, 2018
Understanding the use of NIV in ALS: results of an international ALS specialist survey
Terry D Heiman-Patterson, Merit E Cudkowicz, Mamede De Carvalho, et al.
Page
of 12